These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10404791)

  • 1. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study.
    Vestergaard P; Hermann AP; Orskov H; Mosekilde L
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2286-90. PubMed ID: 10404791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women.
    Nakaoka D; Sugimoto T; Kaji H; Kanzawa M; Yano S; Yamauchi M; Sugishita T; Chihara K
    Osteoporos Int; 2001; 12(7):548-54. PubMed ID: 11527051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
    Milliken LA; Going SB; Houtkooper LB; Flint-Wagner HG; Figueroa A; Metcalfe LL; Blew RM; Sharp SC; Lohman TG
    Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potentially deleterious role of IGFBP-2 on bone density in aging men and women.
    Amin S; Riggs BL; Atkinson EJ; Oberg AL; Melton LJ; Khosla S
    J Bone Miner Res; 2004 Jul; 19(7):1075-83. PubMed ID: 15176989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women.
    Yamaguchi T; Kanatani M; Yamauchi M; Kaji H; Sugishita T; Baylink DJ; Mohan S; Chihara K; Sugimoto T
    Calcif Tissue Int; 2006 Jan; 78(1):18-24. PubMed ID: 16397738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish men.
    Gillberg P; Olofsson H; Mallmin H; Blum WF; Ljunghall S; Nilsson AG
    Calcif Tissue Int; 2002 Jan; 70(1):22-9. PubMed ID: 11907704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study.
    Ueland T; Brixen K; Mosekilde L; Mosekilde L; Flyvbjerg A; Bollerslev J
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1014-8. PubMed ID: 12629078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age, body mass index, current smoking history, and serum insulin-like growth factor-I levels associated with bone mineral density in middle-aged Korean men.
    Rhee EJ; Oh KW; Lee WY; Kim SW; Oh ES; Baek KH; Kang MI; Park CY; Choi MG; Yoo HJ; Park SW
    J Bone Miner Metab; 2004; 22(4):392-8. PubMed ID: 15221500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
    Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
    Tofteng CL; Kindmark A; Brändström H; Abrahamsen B; Petersen S; Stiger F; Stilgren LS; Jensen JE; Vestergaard P; Langdahl BL; Mosekilde L;
    Calcif Tissue Int; 2004 Jan; 74(1):25-34. PubMed ID: 14517714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures.
    Sugimoto T; Nishiyama K; Kuribayashi F; Chihara K
    J Bone Miner Res; 1997 Aug; 12(8):1272-9. PubMed ID: 9258758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis.
    Boonen S; Mohan S; Dequeker J; Aerssens J; Vanderschueren D; Verbeke G; Broos P; Bouillon R; Baylink DJ
    J Bone Miner Res; 1999 Dec; 14(12):2150-8. PubMed ID: 10620075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
    Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
    Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women.
    Seck T; Scheidt-Nave C; Leidig-Bruckner G; Ziegler R; Pfeilschifter J
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):101-6. PubMed ID: 11453958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study.
    Szulc P; Joly-Pharaboz MO; Marchand F; Delmas PD
    Calcif Tissue Int; 2004 Apr; 74(4):322-9. PubMed ID: 15255068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.